Companies › Inventiva Pharma
1 active drug program in 1 registered trial: 1 Phase 3; Gastroenterology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lanifibranor (IVA337) Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04849728 | Lanifibranor (IVA337) | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Gastroenterology | Sep 2027 |
Cash of 97m EUR on 2024-12-31; operating cash outflow about 86m EUR a year; runway about 14 months at that burn, to Feb 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
RDC Clinical Zydus Therapeutics Ipsen Flare Therapeutics Boryung Pharmaceutical Minoryx Therapeutics Dong Wha Pharmaceutical Kowa Company Gilead Sciences
Zydus Therapeutics Elgan Pharma Cinclus Pharma Holding Norgine Green Cross Wellbeing
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.